Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Oncology | Pathology | Urology | Journal

Back to Journal Articles

Bladder Cancer Survival Similar for Partial, Radical Cystectomy

Last Updated: September 20, 2012.

 

No difference in metastasis-free or cancer-specific survival after median 6.2-year follow-up

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For select patients with bladder cancer, there is no difference in metastasis-free or cancer-specific survival with partial cystectomy or radical cystectomy, but there is an increased risk for intravesical recurrence for those treated with partial cystectomy, according to research published in the October issue of The Journal of Urology.

THURSDAY, Sept. 20 (HealthDay News) -- For select patients with bladder cancer, there is no difference in metastasis-free or cancer-specific survival with partial cystectomy (PC) or radical cystectomy (RC), but there is an increased risk for intravesical recurrence for those treated with PC, according to research published in the October issue of The Journal of Urology.

In an effort to evaluate the long-term oncologic outcomes in bladder cancer, John J. Knoedler, M.D., of the Mayo Clinic in Rochester, Minn., and colleagues conducted a matched, case-control study involving 86 patients who underwent PC and 167 who underwent RC.

After a median follow-up period of 6.2 years, the researchers found no between-group difference in the 10-year distant recurrence-free survival or cancer-specific survival. While significantly fewer PC-treated patients experienced an extravesical pelvic tumor recurrence compared with RC-treated patients (5 versus 17 percent), PC-treated patients were at higher risk of intravesical tumor recurrence. Intravesical recurrence occurred in 38 percent of PC-treated patients, and, of these, 19 percent eventually underwent a RC procedure.

"Our matched analysis demonstrated no difference in cancer-specific survival or metastasis-free survival between patients treated with PC and those treated with RC," the authors write. "Patients who undergo PC remain at risk for intravesical recurrence with almost 20 percent requiring subsequent RC. Thus patients considering PC should be counseled and surveilled accordingly."

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Linaclotide Relieves Symptoms of IBS With Constipation Next: Duration of Antiplatelet Drugs for Drug-Eluting Stents Studied

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.